Comparison of metformin, pioglitazone and vitamin E on nonalcoholic fatty liver disease

Comparison of therapeutic effects of metformin, pioglitazone and vitamin E on nonalcoholic fatty liver disease patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013071313069N2

Enrollment

Registered

2013-09-22

Start date

2007-06-06

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nonalcoholic fatty liver disease. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Group A:Tablet metformine 2gr/day orally (two 500 mg tablets q 12h) for 12 weeks. Intervention 2: Group B: Tablet pioglitazone 30 mg/day orally ( one 15 mg tablet q 12h) for 12 weeks.

Treatment - Drugs

Group A:Tablet metformine 2gr/day orally (two 500 mg tablets q 12h) for 12 weeks

Group B: Tablet pioglitazone 30 mg/day orally ( one 15 mg tablet q 12h) for 12 weeks

Group C: Tablet vitamin E 800 IU/day orally (One 400 IU tablet q 12h) for 12 weeks

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Age above 18 year and Non-alcoholic fatty liver disease alone with negative hepatitis serology Exclusion criteria: clinical manifestation of liver disease, icter, steroid and alcohol use, diabetes, pregnancy, hypothyroidism, renal failure.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Liver enzymes, Blood sugar, Insulin. Timepoint: Before and 12 weeks after treatment. Method of measurement: Laboratory assessment (ELISA).	—

Secondary

Measure	Time frame
Liver echo pattern. Timepoint: Before and 12 weeks after treatment. Method of measurement: Sonographic assessment.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mohammad Rasoul Ghadami

Kermanshah University of Medical Sciences

mr_ghadami@yahoo.com mrghadami@kums.ac.ir+98 83 1427 6310

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026